Early Phase 1 Pancreatitis Trial, Recruiting NCT07314489 Sponsor: Shanghai Changzheng Hospital Condition: Pancreatitis
Back to Pancreatitis

Early Phase 1 Pancreatitis Trial, Recruiting

NCT07314489
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are male or female, Chinese, and aged 18 years or older
  • You have been clearly diagnosed with chronic pancreatitis (long-term inflammation of the pancreas)
  • Your glycated hemoglobin (HbA1c) blood sugar level is between 4% and 6% (a measure of average blood sugar over several months)
  • Your fecal elastase-1 (FE-1) test result is below 100 µg/g, which is a stool test that checks how well your pancreas is working (confirm with trial site)

Who may not be able to join:

  • You have a history of diabetes or prediabetes, or your recent blood sugar measurements are above certain levels
  • You have tested positive for certain antibodies related to the insulin-producing cells in your pancreas (confirm with trial site)
  • You are currently taking or have previously taken pancreatic enzyme replacement therapy (digestive enzyme supplements)
  • You are known to be allergic to any ingredients in pancreatic enzyme replacement medications
  • Your pancreatic enzyme insufficiency is caused by something other than chronic pancreatitis, such as having had part of your stomach or intestine removed
  • You have had pancreatic surgery (other than a specific type of procedure called ERCP)
  • You have moderate to severe chronic kidney disease (stage 3, 4, or 5)
  • You have serious, advanced liver disease
  • You are currently taking steroid medications (such as corticosteroids)
  • You are pregnant or breastfeeding
  • You have been diagnosed with a malignant (cancerous) tumor

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 86-13918507887

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Shanghai Changzheng Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The changes in glucose profile before and after pancreatic enzyme intervention

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov